NCT04879017 - FHD-286 in Subjects With Metastatic Uveal Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG

FHD-286

FHD-286 as a single agent

Trial Locations (11)

Columbia University, Herbert Irving Comprehensive Cancer Center, New York

Memorial Sloan Kettering Cancer Center, New York

Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia

University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami

Sarah Cannon Research Institute, Nashville

MD Anderson Cancer Center, Houston

The Angeles Clinic and Research Institute, Los Angeles

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Institute Curie Hospital, Paris

Leiden University Medical Center, Leiden